A hierarchical system of differential equations was used to model the response of CML cells to imatinib therapy in [5]; this model fit the biphasic nature of decline in BCR-ABL positive cells during imatinib treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.